Interaction of calcium-bound c-reactive protein with fibronectin is controlled by pH -: In vivo implications

被引:48
作者
Suresh, MV [1 ]
Singh, SK [1 ]
Agrawal, A [1 ]
机构
[1] E Tennessee State Univ, James H Quillen Coll Med, Dept Pharm, Johnson City, TN 37614 USA
关键词
D O I
10.1074/jbc.M409054200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
C-reactive protein (CRP) binds with high affinity to fibronectin (Fn), a major component of the extracellular matrix (ECM), but at physiological pH the binding is inhibited by calcium ions (Ca2+). Because CRP circulates in the blood in Ca2+-bound form, the occurrence of CRP-Fn interactions in vivo has been doubtful. To define the basis of inhibition of CRP-Fn interaction by Ca2+ at pH 7.0, we hypothesized that Fn-binding site on CRP consisted of amino acids co-ordinating Ca2+. Site-directed mutagenesis of amino acids co-ordinating Ca2+ drastically decreased the binding of CRP to Fn, indicating that the Ca2+-binding site indeed formed the Fn-binding site. To determine the requirements for possible interaction between Ca2+-bound CRP and Fn, we investigated inhibition of CRP-Fn interaction by Ca2+ as a function of pH. Ca2+ did not inhibit binding of CRP to Fn at pH 6.5 and lower. The contrasting Fn binding properties of CRP at physiological and mildly acidic pH indicated that the interaction of Ca2+-bound CRP with Fn was controlled by pH. We conclude that the inhibition of binding of CRP to Fn by Ca2+ at pH 7.0 is a mechanism to prevent CRP-Fn interactions under normal conditions. CRP, in its Ca2+-bound state, is capable of binding Fn but only at the inflammatory sites and tumors with low pH. CRP, Fn, and the ECM all have been implicated in cancer. Taken together our data raise the possibility that CRP-Fn interactions may change the architecture of ECM to modify the development of tumors.
引用
收藏
页码:52552 / 52557
页数:6
相关论文
共 49 条
[1]   A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide [J].
Agrawal, A ;
Simpson, MJ ;
Black, S ;
Carey, MP ;
Samols, D .
JOURNAL OF IMMUNOLOGY, 2002, 169 (06) :3217-3222
[2]  
AGRAWAL A, 1992, J BIOL CHEM, V267, P25352
[3]  
Agrawal A, 1997, J IMMUNOL, V158, P345
[4]   THERAPEUTIC EFFECTS OF A SYNTHETIC PEPTIDE OF C-REACTIVE PROTEIN IN PRECLINICAL TUMOR-MODELS [J].
BARNA, BP ;
EPPSTEIN, DA ;
THOMASSEN, MJ ;
NESTOR, JJ ;
HO, T ;
MEDENDORP, SV ;
DEODHAR, SD .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (03) :171-176
[5]   FIBROLAMELLAR CARCINOMA OF THE LIVER - AN IMMUNOHISTOCHEMICAL STUDY OF 19 CASES AND A REVIEW OF THE LITERATURE [J].
BERMAN, MA ;
BURNHAM, JA ;
SHEAHAN, DG .
HUMAN PATHOLOGY, 1988, 19 (07) :784-794
[6]   Possible protective role for c-reactive protein in atherogenesis - Complement activation by modified lipoproteins halts before detrimental terminal sequence [J].
Bhakdi, S ;
Torzewski, M ;
Paprotka, K ;
Schmitt, S ;
Barsoom, H ;
Suriyaphol, P ;
Han, SR ;
Lackner, KJ ;
Husmann, M .
CIRCULATION, 2004, 109 (15) :1870-1876
[7]   The phosphocholine and the polycation-binding sites on rabbit C-reactive protein are structurally and functionally distinct [J].
Black, S ;
Agrawal, A ;
Samols, D .
MOLECULAR IMMUNOLOGY, 2003, 39 (16) :1045-1054
[8]   C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids [J].
Chang, MK ;
Binder, CJ ;
Torzewski, M ;
Witztum, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) :13043-13048
[9]  
DAVID L, 1994, CANCER, V73, P518, DOI 10.1002/1097-0142(19940201)73:3<518::AID-CNCR2820730305>3.0.CO
[10]  
2-T